Pazopanib: An antiangiogenic drug in perspective

Carlos A. Castaneda, Henry L. Gomez

Research output: Contribution to journalScientific review

20 Scopus citations

Abstract

Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity. © 2009 Future Medicine Ltd.
Original languageAmerican English
Pages (from-to)1335-1348
Number of pages14
JournalFuture Oncology
DOIs
StatePublished - 1 Dec 2009
Externally publishedYes

Fingerprint Dive into the research topics of 'Pazopanib: An antiangiogenic drug in perspective'. Together they form a unique fingerprint.

  • Cite this